A therapeutic formulation for preventing posttraumatic osteoarthritis after joint injuries

Value Proposition

Osteoarthritis (OA) is an affliction of the joints that affects approximately 27 million people in the U.S . Posttraumatic osteoarthritis (PTOA), or osteoarthritis occuring after joint injury, accounts for approximately 12% of these cases and arises rapidly after acute joint insult commonly in the knee or ankle. The standard-of-care for treating severe joint injury is surgical restoration, however there is no disease modifying treatment for the lasting debilitation of PTOA.

Technology

Inventors at Duke University have developed an intra-articular chrondoprotective therapeutic formulation using FDA-approved drugs that prevents the development of posttraumatic osteoarthritis. This invention is intended to be administered to patients immediately after knee or ankle injuries to prevent the development of PTOA. This technology has been demonstrated in animal models.

Advantages

  • A first-in-class preventative treatment for posttraumatic osteoarthritis
  • Formulation is easily prepared and injected
  • Can lead to complete, lasting recovery of common joint fractures and injuries such as ankle and knee